Immunocore Holdings Plc Sponsored ADR IMCR 深 沪
已收盘 12-19 16:00:00 美东时间
35.97
+0.070
+0.19%
华盛通- 最 高40.7147
- 今 开36.13
- 成交量 44.00万股
- 最 低 35.2219
- 昨 收 35.90
- 总市值 15.79亿
- 52周最高 40.7147
- 市盈率 静 --
- 换手率 1.00%
- 52周最低 23.15
- 委 比 93.72%
- 总股本 4389.71万
- 历史最高 76.98
- 量 比 1.67
- 振 幅 15.30%
- 历史最低 1.10
- 每 手 1
- 风险率 3.13%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Immunocore to present at the 2025 Jefferies Global Healthcare Conference
Immunocore Holdings plc announced that its management will participate in the 2025 Jefferies Global Healthcare Conference. The company, which develops transformative immunomodulating medicines for cancers, infectious diseases, and autoimmune conditions, has its lead oncology therapy, KIMMTRAK, approved for the treatment of specific melanoma patients.
06-02 11:00
Analyst Expectations For Immunocore Hldgs's Future
Immunocore Hldgs (NASDAQ:IMCR) underwent analysis by 7 analysts in the last qua...
2024-09-17 20:00
Reported Saturday, Immunocore Presented Phase 1 Data With Brenetafusp In Patients With Platinum-Resistant Ovarian Cancer At The 2024 ESMO Congress
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancerBrenetafusp is clinically active as monotherapy and in combination with chemotherapy in heavily
2024-09-16 16:53
Cantor Fitzgerald Reiterates Overweight on Immunocore Hldgs
Cantor Fitzgerald analyst Eric Schmidt reiterates Immunocore Hldgs (NASDAQ:IMCR) with a Overweight.
2024-09-10 01:04
Immunocore Finance Chief Brian Di Donato to Resign
07:19 AM EDT, 08/29/2024 (MT Newswires) -- Immunocore Holdings (IMCR) said Thursday that Brian Di Donato is planning to step down as chief financial officer at the end of the year to become CEO of a private biotechnology company. The company said it will initiate a search for Di Donato's successor, ...
2024-08-29 19:19
Immunocore CFO And Head Of Strategy, Brian Di Donato, Informs His Plans To Leave At Year-End; Company To Initiate Search For New CFO
Di Donato has accepted the role of Chief Executive Officer at a private, early-stage biotech headquartered in San Diego, California. Immunocore will initiate a search for a new CFO. Brian will remain as the Company's CFO and Head of Strategy through the end of 2024, to ensure a smooth transition.
2024-08-29 19:19
The Latest Analyst Ratings For Immunocore Hldgs
In the last three months, 7 analysts have published ratings on Immunocore Hldgs (NASDAQ:IMCR), offering a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the prec...
2024-08-28 20:00
HC Wainwright & Co. Reiterates Buy on Immunocore Hldgs, Maintains $100 Price Target
HC Wainwright & Co. analyst Patrick Trucchio reiterates Immunocore Hldgs (NASDAQ:IMCR) with a Buy and maintains $100 price target.
2024-08-28 18:14
